S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

This study has been completed.

Study NCT00068783 Information provided by Southwest Oncology Group

First Received: September 10, 2003 Last Updated: January 11, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	October 2010
Primary Completion Date:	June 2007 (Final data collection date for primary outcome measure)

Publications:

Samlowski WE, Moon J, Tuthill RJ, et al.: A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331). [Abstract] J Clin Oncol 27 (Suppl 15): A-9056, 2009.